Zepbound and Yeast Infections in Women
Based on available evidence, Zepbound (tirzepatide) does not directly cause vaginal yeast infections in women. The FDA drug label 1 does not list yeast infections as a known adverse effect, and clinical research on tirzepatide [2-3] has not identified vulvovaginal candidiasis as an associated complication.
Understanding the Evidence Gap
The provided evidence extensively covers treatment guidelines for vulvovaginal candidiasis [4-5] but contains no data linking tirzepatide to yeast infections. The research on tirzepatide focuses primarily on:
- Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) occurring in 16-20% of patients 6
- Metabolic effects on glucose control and weight loss 7, 8
- Rare cardiovascular complications from severe electrolyte disturbances 2
- Other adverse events like palpitations, musculoskeletal pain, and headaches 9
Why This Question Matters
Vulvovaginal candidiasis affects approximately 75% of women at least once in their lifetime 10, 11, 10, with 40-45% experiencing recurrent episodes [4-12]. Common risk factors include:
- Uncontrolled diabetes mellitus
- Antibiotic use
- Immunosuppression
- Corticosteroid therapy
Clinical Considerations for Tirzepatide Users
If a woman on Zepbound develops a yeast infection, consider these factors:
- Improved glycemic control from tirzepatide may actually reduce yeast infection risk in diabetic patients, as hyperglycemia is a known predisposing factor 4
- The infection is likely coincidental rather than medication-related
- Standard treatment protocols apply: single-dose fluconazole 150 mg or topical azole therapy for 3-7 days 10, 11, 10
When to Investigate Further
Evaluate for other causes if yeast infections occur:
- Check HbA1c to ensure adequate diabetes control
- Review concurrent antibiotic use
- Assess for immunosuppression
- Consider recurrent VVC (≥3 episodes/year) requiring maintenance therapy with fluconazole 150 mg weekly for 6 months 10, 5
The absence of any documented association between tirzepatide and vulvovaginal candidiasis in clinical trials involving thousands of patients 6, 7 strongly suggests this is not a medication-related adverse effect.